Research and Development Investment: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.

R&D Investment Trends: Jazz vs. Halozyme (2014-2023)

__timestampHalozyme Therapeutics, Inc.Jazz Pharmaceuticals plc
Wednesday, January 1, 20147969600085181000
Thursday, January 1, 201593236000135253000
Friday, January 1, 2016150842000162297000
Sunday, January 1, 2017150643000198442000
Monday, January 1, 2018150252000226616000
Tuesday, January 1, 2019140804000299726000
Wednesday, January 1, 202034236000335375000
Friday, January 1, 202135672000505748000
Saturday, January 1, 202266607000590453000
Sunday, January 1, 202376363000849658000
Monday, January 1, 202479048000
Loading chart...

Infusing magic into the data realm

A Decade of R&D Investment: Jazz Pharmaceuticals vs. Halozyme Therapeutics

In the competitive landscape of pharmaceuticals, research and development (R&D) investment is a critical driver of innovation and growth. Over the past decade, Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures.

From 2014 to 2023, Jazz Pharmaceuticals consistently increased its R&D spending, peaking in 2023 with an impressive 850% growth compared to 2014. This strategic investment underscores Jazz's commitment to expanding its drug pipeline and enhancing its market position. In contrast, Halozyme Therapeutics experienced fluctuations, with a notable dip in 2020, where R&D expenses dropped by nearly 77% from their 2016 peak. However, by 2023, Halozyme's investment rebounded, reflecting a renewed focus on innovation.

These trends highlight the dynamic nature of R&D investment strategies and their impact on the pharmaceutical industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025